Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Dallas, TX, US. The stock last traded at $76.99, up 0.00% on the session, giving a market capitalisation of $1.63B. On trailing twelve-month figures it carries a trailing P/E of -16.77, a net margin of 0.0%. Its beta of 2.65 implies it has historically moved more than the broad market.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Forte Biosciences, Inc. is most often compared with the following Healthcare names: